Company Overview
| Stock Name | 康寧傑瑞生物製藥 - B |
|---|---|
| Stock Code | 09966 |
| Company Full Name | 康寧傑瑞生物製藥 - B |
| Industry | 醫療保健 |
| Principal Activities | 主要從事生物制藥業務。 |
| Listing Date | 2019-12-12 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省蘇州市蘇州工業園區星湖街218號C23樓401和501室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.alphamabonc.com/ |
| Share Registrar | |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 10.20 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 49.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 914,960,400 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 13.5 |
|---|---|
| First Day Open | HK$ 13.0 |
| First Day Change | 32.35% |
| First Day Volume | 115582000.0 |
| First Day Turnover | 1499270000.0 |
Use of Proceeds
| Use of Proceeds | 1、約50%（或854.6百萬港元）將用于我們的核心產品KN046的研發及商業化； 2、約20%（或341.8百萬港元）將用于KN026的研發及商業化； 3、約5%（或85.5百萬港元）將用于KN019的研發； 4、約15%（或256.4百萬港元）將用于我們于蘇州的新制造及研發設施的建設； 5、約10%（或170.9百萬港元）將用于我們的早期管線及作營運資金及一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (3)
摩根士丹利亚洲有限公司 CE AAD291
中信证券（香港）有限公司 CE AAK249
富瑞金融集团香港有限公司 CE ATS546
Overall Coordinators (3)
摩根士丹利亚洲有限公司 CE AAD291
中信里昂证券有限公司 CE AAB893
富瑞金融集团香港有限公司 CE ATS546
Joint Bookrunners (7)
摩根士丹利亚洲有限公司 CE AAD291
中信里昂证券有限公司 CE AAB893
富瑞金融集团香港有限公司 CE ATS546
交银国际证券有限公司 CE APJ121
复星国际证券有限公司 CE AAF432
东方证券（香港）有限公司 CE AVD362
中银国际亚洲有限公司 CE AET863
Joint Lead Managers (7)
摩根士丹利亚洲有限公司 CE AAD291
中信里昂证券有限公司 CE AAB893
富瑞金融集团香港有限公司 CE ATS546
交银国际证券有限公司 CE APJ121
复星国际证券有限公司 CE AAF432
东方证券（香港）有限公司 CE AVD362
中银国际亚洲有限公司 CE AET863
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Lake Bleu Prime Healthcare Master Fund Limited | 103,193,400 HKD | — | 5.60% | — | 6 months | 2020-06-12 |
| 2 | Matthews Asia Funds | 192,616,800 HKD | — | 10.50% | — | 6 months | 2020-06-12 |
| 3 | OrbiMed Funds | 137,608,200 HKD | — | 7.50% | — | 6 months | 2020-06-12 |
| 4 | 景林资产管理有限公司 | 137,577,600 HKD | — | 7.50% | — | 6 months | 2020-06-12 |
| 5 | 绿叶制药集团有限公司 | 34,394,400 HKD | — | 1.90% | — | 6 months | 2020-06-12 |
| 6 | 摩根士丹利亚洲有限公司 | 103,183,200 HKD | — | 5.60% | — | 6 months | 2020-06-12 |
| 7 | 泰康人寿保险有限责任公司 | 206,376,600 HKD | — | 11.30% | — | 6 months | 2020-06-12 |
Directors & Management
| Chairman | 徐霆 |
|---|---|
| Company Secretary | 蔣銳;陳濼而 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 徐霆及家族成員(34.00%);張喜田(9.15%);薛傳校(9.15%);Advantech Capital II AlphaMab Partnership L.P.(5.30%) |
|---|
